LeadIQ logo
Learn more at LeadIQ.com

Insights

Degrader Partnerships Biohaven’s protein degrader pipeline (BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy) offers high-value licensing or co-development opportunities in autoimmune targets, supported by pivotal trials expected in 2026 and compelling biomarker data.

Neurology Collaboration BHV-8100, an oral brain-penetrant PKM2 modulator, creates partnering opportunities in metabolic restoration and immunomodulation for CNS disorders, with favorable pharmacokinetics and early human data enabling convenient dosing.

Epilepsy Momentum Opakalim (Kv7 activator) shows improved seizure control in idiopathic generalized epilepsy, indicating potential for co-development or licensing in epilepsy portfolios and related neurology indications ahead of 2026 topline results.

Autoimmune Value Early data from autoimmune programs demonstrate deep reductions in disease-driving antibodies (TSHR-IgG1) and rapid biochemical improvements, signaling strong interest for autoantibody-lowering platforms in Graves’ disease and IgA nephropathy.

Partnership Readiness As a mid-sized biotech with ongoing clinical catalysts and a patient-first culture, Biohaven presents scalable partnership opportunities across CNS, autoimmune, and metabolic programs, including licensing, out-licensing, or co-development with larger pharma.

Biohaven Tech Stack

Biohaven uses 8 technology products and services including Cloudflare, jQuery, Web Vitals, and more. Explore Biohaven's tech stack below.

  • Cloudflare
    Content Management System
  • jQuery
    Javascript Libraries
  • Web Vitals
    Javascript Libraries
  • Really Simple Discovery
    Miscellaneous
  • HSTS
    Security
  • Adobe Tag Manager
    Tag Management
  • Bootstrap
    UI Frameworks
  • Adobe Fonts
    Web Fonts

Media & News

Biohaven's Email Address Formats

Biohaven uses at least 2 format(s):
Biohaven Email FormatsExamplePercentage
First.Last@biohavenpharma.comJohn.Doe@biohavenpharma.com
96%
Last.First@biohavenpharma.comDoe.John@biohavenpharma.com
3%
First.L@biohavenpharma.comJohn.D@biohavenpharma.com
1%
FLast@biohaven.comJDoe@biohaven.com
77%
First.Last@biohaven.comJohn.Doe@biohaven.com
17%
Last@biohaven.comDoe@biohaven.com
6%

Frequently Asked Questions

What is Biohaven's phone number?

Minus sign iconPlus sign icon You can contact Biohaven's main corporate office by phone at
+1-203-214-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Biohaven's stock symbol?

Minus sign iconPlus sign iconBiohaven is a publicly traded company; the company's stock symbol is BHVN.

What is Biohaven's official website and social media links?

Minus sign iconPlus sign iconBiohaven's official website is biohaven.com and has social profiles on LinkedIn.

What is Biohaven's SIC code NAICS code?

Minus sign iconPlus sign iconBiohaven's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Biohaven have currently?

Minus sign iconPlus sign iconAs of July 2026, Biohaven has approximately 386 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Financial Officer: M. B.Vice President Corporate Operations: R. G.Vice President Technical Operations: J. G.. Explore Biohaven's employee directory with LeadIQ.

What industry does Biohaven belong to?

Minus sign iconPlus sign iconBiohaven operates in the Biotechnology Research industry.

What technology does Biohaven use?

Minus sign iconPlus sign iconBiohaven's tech stack includes CloudflarejQueryWeb VitalsReally Simple DiscoveryHSTSAdobe Tag ManagerBootstrapAdobe Fonts.

What is Biohaven's email format?

Minus sign iconPlus sign iconBiohaven's email format typically follows the pattern of First.Last@biohavenpharma.com. Find more Biohaven email formats with LeadIQ.

How much funding has Biohaven raised to date?

Minus sign iconPlus sign icon As of July 2026, Biohaven has raised $2.1B in funding. The last funding round occurred on Nov 12, 2025.

When was Biohaven founded?

Minus sign iconPlus sign iconBiohaven was founded in 2022.
Biohaven logo

Biohaven

Biotechnology ResearchConnecticut, United States201-500 Employees

Biohaven is a mid-sized biotechnology research company based in New Haven, Connecticut. It concentrates on developing novel therapies intended to address unmet patient needs through scientific innovation and a patient-first culture. The organization relies on an agile, resilient team that seeks to challenge conventional approaches to advance life-changing treatments.

Its pipeline includes protein-degrader programs for autoimmune diseases, with BHV-1300 targeting Graves’ disease and BHV-1400 for IgA nephropathy, and pivotal studies planned for mid-2026 following encouraging early biomarker data. The company is also advancing an oral PKM2 modulator, BHV-8100, with first-in-human dosing reported, and pursuing epilepsy programs such as opakalim that aim to improve seizure control.

Section iconCompany Overview

Phone number
+1-203-214-****
Website
biohaven.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
BHVN
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2022
Employees
201-500

Section iconMedia & News

Section iconFunding & Financials

  • $2.1B

    Biohaven has raised a total of $2.1B of funding over 12 rounds. Their latest funding round was raised on Nov 12, 2025as a post_ipo_equity.

  • $100M$250M

    Biohaven's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $2.1B

    Biohaven has raised a total of $2.1B of funding over 12 rounds. Their latest funding round was raised on Nov 12, 2025as a post_ipo_equity.

  • $100M$250M

    Biohaven's revenue is estimated to be in the range of $100M$250M

Company Leadership

  • Stylized image of a person
    M. B.
    Chief Financial Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    R. G.
    Vice President Corporate Operations
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. G.
    Vice President Technical Operations
    Phone icon
    Mobile Phone
  • Stylized image of a person
    E. H.
    Vice President Clinical Operations
    Phone icon
    Mobile Phone
  • Stylized image of a person
    L. D.
    Vice President Clinical Operations
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    R. B. M.
    Owner
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. A.
    Senior Vice President Finance
    Phone icon
    Mobile Phone
  • Stylized image of a person
    R. G.
    Vice President Corporate Operations
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. G.
    Vice President Technical Operations
    Phone icon
    Mobile Phone
  • Stylized image of a person
    E. H.
    Vice President Clinical Operations
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.